Ardelyx, Inc. announced that on March 11, 2021, Gordon Ringold, Ph.D., notified the Board of his decision to resign from the Board, and the Nominating and Governance Committee of the Board, of which he served as Chairman, effective at 11:59 p.m. on March 11, 2021, in order to focus on his other business commitments. Dr. Ringold’s resignation is not due to any disagreement with the Company on any matter relating to the Company’s operations, policies or practices. On March 11, 2021, the Company appointed Muna Bhanji as a member of the Board, effective immediately, to serve as a Class III director until the Company’s 2023 Annual Meeting of Stockholders and until her successor is duly elected and qualified, or until her earlier death, resignation or removal. Following Ms. Bhanji’s appointment and the effectiveness of Dr. Ringold’s resignation, the Class III directors will consist of Robert Bazemore, Richard Rodgers and Ms. Bhanji. Ms. Bhanji was also appointed to serve as a member of the Nominating and Governance Committee of the Board effective immediately, and William Bertrand, Jr., Esq., was appointed to serve as the Chairman of the Nominating and Governance Committee effective as of the effective date of Dr. Ringold’s resignation. Following the effective date of Ms. Bhanji’s appointment and Dr. Ringold’s resignation, the Nominating and Governance Committee will consist of William Bertrand, Jr., Esq., as chairman, Geoffrey Block, M.D, Onaiza Cadoret-Manier and Ms. Bhanji.
Ardelyx, Inc. is a biopharmaceutical company. The Company focuses on discovery, development, and commercialization of advanced medicines that meet significant unmet medical needs. It has two commercial products IBSRELA (tenapanor) and XPHOZAH. Its product pipeline includes RDX013 Program and RDX020 Program. Tenapanor is a small molecule therapy in development for the treatment of or the control of hyperphosphatemia or serum phosphorus in adult patients with chronic kidney disease (CKD) on dialysis. Tenapanor has a mechanism of action and acts locally in the gut to inhibit the sodium hydrogen exchanger 3 (NHE3). IBSRELA is developed for the treatment of patients with irritable bowel syndrome with constipation (IBS-C). XPHOZAH is a medicine for the control of serum phosphorus in adult patients with CKD on dialysis. RDX013 Program is a small molecule potassium secretagogue program for the treatment of hyperkalemia. RDX020 Program is a small molecule for treating metabolic acidosis.